Skip to main content
OpenTrials
Completed

NCT Number: NCT03977961

The Six-Minute Walking Test (6MWT) as a Measure of Functional Impairment in Lumbar Degenerate Disc Disease.

The study determines the reliability and validity of the 6-Minute Walking Test (6MWT) in patients with lumbar degenerative disc disease (DDD).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Kantonsspital St. Gallen / Department of Neurosurgery

Sankt Gallen, Canton of St. Gallen, 9000, Switzerland

About this study

The purposes of the study is to assess the ability of the 6-Minute Walking Test (6MWT) as a reliable and standardized objective outcome assessment and its relation to already established subjective patient reported outcome measures in patients suffering from lumbar degenerative disc disease. We want to use an existing smartphone-application that uses global positioning system (GPS) coordinates to measure walking distance. Applying self- measurement of the 6MWT before and after a therapeutic intervention, we determine objective functional impairment (OFI) in patients. The results of this study add to the understanding of achievable objective outcomes after therapeutic interventions applied to patients with DDD and examines patients acceptance for smartphone based self-measurement.

Primary Objectives The primary objective is to determine the reliability and validity of the 6-Minute Walking Test (6MWT) in patients with lumbar degenerative disc disease (DDD)

Secondary objectives are

  • to correlate objective functional impairment (OFI) with already established patient-rated outcome measures (PROMs) in the sense of cross-validation.
  • To correlate OFI, as determined by the 6MWT with OFI that is determined by another objective test, the TUG test
  • to then analyze the change in OFI in patients before and after surgical intervention
  • to determine whether patients prefer the objective (6MWT) or subjective (PROMs) repeated assessment of their functional condition.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient scheduled for spine surgery with one of the following diagnosis (1) lumbar disc herniation (LDH), (2) lumbar spinal stenosis lumbar (LSS) or lumbar DDD with or without instability requiring lumbar fusion (transforaminal lumbar interbody fusion, posterior lumbar interbody fusion, or extreme lateral interbody fusion)
  • Male and Female subjects ≥ 18 years
  • Written informed consent

Exclusion criteria

  • Pregnancy
  • Inability to walk (extreme pain or severe neurological deficits)
  • Severe Chronic Obstructive Lung Disease (COPD) corresponding to ≥ Gold III
  • Severe heart failure corresponding to ≥ New York Heart Association (NYHA) III
  • Lung cancer and diffuse parenchymal lung disease
  • Other medical reasons interfering with the patient's ability to walk and perform the 6MWT (e.g., osteoarthritis disease of the lower extremities, Parkinson's disease, heart failure, hip or knee prosthesis etc.)
  • Unavailability for follow up and/or inability to complete assessment (planning to move, no smartphone, etc.).

Treatment and study plan

Primary outcomes

  1. Raw walking distance

    Time frame: 4-12 weeks

    Raw walking distance (in m), as measured with the 6MWT, between the baseline- (before surgery) and follow-up assessment

Secondary outcomes

  1. TTFS

    Time frame: 4-12 weeks

    Difference in Time to First Symptoms (TTFS; in sec) as measured by the 6MWT, between the baseline- and follow-up assessment

  2. DTFS

    Time frame: 4-12 weeks

    Difference in Distance to First Symptoms (DTFS, in m), as measured by the 6MWT, between the baseline- and follow-up assessment

  3. Zurich Claudication Questionnaire (ZCQ)

    Time frame: 4-12 weeks

    Difference in PROM, as measured by the Zurich Claudication Questionnaire (ZCQ average score, range 0 (best) - 4,5 (worst), between the baseline- and follow-up assessment.

  4. Core Outcome Measures Index (COMI)

    Time frame: 4-12 weeks

    Difference in health-related quality of life (hrQoL), as measured by the Core Outcome Measures Index (COMI average score, range 0 (best) - 10 (worst)), between the baseline- and follow-up assessment

  5. TTFS/ZCQ baseline

    Time frame: 4-12 weeks

    Correlation of TTFS/DTFS in the 6MWT with the ZCQ score at baseline

  6. TTFS/ZCQ follow-up

    Time frame: 4-12 weeks

    Correlation of TTFS in the 6MWT with the ZCQ score at follow-up

  7. TTFS/COMI baseline

    Time frame: 4-12 weeks

    Correlation of TTFS/DTFS in the 6MWT with the COMI score at baseline

  8. TTFS/COMI follow-up

    Time frame: 4-12 weeks

    Correlation of TTFS/DTFS in the 6MWT with the COMI score at follow-up

  9. TTFS/TUG baseline

    Time frame: 4-12 weeks

    Correlation of TTFS/DTFS in the 6MWT with the Timed up go Test (TUG) at baseline

  10. TTFS/TUG follow-up

    Time frame: 4-12 weeks

    Correlation of TTFS/DTFS in the 6MWT with the TUG at follow-up

  11. Test-retest reliability of the 6MWT

    Time frame: 6 weeks to 1 day before surgery as well as 4-12 weeks after surgery

    Test-retest reliability of the 6MWT in patients with lumbar degenerate disc disease, tested two consecutive times with the 6MWT App (within 3 days) before as well as after surgery.

Sponsors and collaborators

Lead sponsor

Cantonal Hospital of St. Gallen

Other

Collaborators

  • PD Dr. med. Martin Stienen, Klinik für Neurochirurgie, Universitätsspital Zürich
  • PD Dr. med. Oliver Gautschi, Neuro- und Wirbelsäulen Zentrum Zentral-schweiz, Luzern

Registry information

Acronym: 6MWT-DDD

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Jun 6, 2019
Registry last updated
Jul 26, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.